Ryan Drenan to Nicotinic Antagonists
This is a "connection" page, showing publications Ryan Drenan has written about Nicotinic Antagonists.
Connection Strength
0.870
-
Arias HR, Jin X, Feuerbach D, Drenan RM. Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula. Int J Biochem Cell Biol. 2017 11; 92:202-209.
Score: 0.603
-
Berry JN, Engle SE, McIntosh JM, Drenan RM. a6-Containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity. Neuroscience. 2015 Sep 24; 304:161-75.
Score: 0.129
-
Wang Y, Lee JW, Oh G, Grady SR, McIntosh JM, Brunzell DH, Cannon JR, Drenan RM. Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function a6* nAChRs. J Neurochem. 2014 Apr; 129(2):315-27.
Score: 0.116
-
Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, McKinney S, Whiteaker P, Bencherif M, Lester HA, Marks MJ. Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology. 2010 Jun; 58(7):1054-66.
Score: 0.022